Continuous glucose monitoring (CGM) in advanced neurodegenerative diseases

Continuous glucose monitoring (CGM) in advanced neurodegenerative diseases - CGM in neurodegenerative diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220372

Enrollment

Registered

2018-08-03

Start date

2016-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegenerative diseases0

Interventions

Intervention type: Name of intervention:None Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration:None None None Dosing frequency /

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Bedridden neurodegenerative diseases under enteral feeding

Exclusion criteria

Exclusion criteria: Severe systemic diseases, use of mechanical ventilation

Design outcomes

Primary

Measure	Time frame
hypo- and/or hyperglycemia, and glucose fluctuation	—

Countries

Japan

Contacts

Public ContactHiroyuki Todo

National Health Organization Hyogo-Chuo National Hospital

mailbox@hch.hosp.go.jp+81-79-563-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026